Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $0.06.

  • Mirum Pharmaceuticals' EPS (Basic) rose 12000.0% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.85, marking a year-over-year increase of 5913.46%. This contributed to the annual value of -$1.85 for FY2024, which is 5370.12% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported EPS (Basic) of $0.06 as of Q3 2025, which was up 12000.0% from -$0.12 recorded in Q2 2025.
  • Mirum Pharmaceuticals' EPS (Basic)'s 5-year high stood at $1.89 during Q4 2021, with a 5-year trough of -$1.94 in Q2 2023.
  • For the 5-year period, Mirum Pharmaceuticals' EPS (Basic) averaged around -$0.69, with its median value being -$0.8 (2023).
  • As far as peak fluctuations go, Mirum Pharmaceuticals' EPS (Basic) soared by 23118.57% in 2021, and later plummeted by 15187.72% in 2022.
  • Mirum Pharmaceuticals' EPS (Basic) (Quarter) stood at $1.89 in 2021, then tumbled by 151.88% to -$0.98 in 2022, then increased by 11.0% to -$0.87 in 2023, then soared by 42.6% to -$0.5 in 2024, then surged by 111.99% to $0.06 in 2025.
  • Its last three reported values are $0.06 in Q3 2025, -$0.12 for Q2 2025, and -$0.3 during Q1 2025.